MiBo ThermoFlo Lid Temperature Evaluation

Dry Eye Clinical Trial

Official title:

MiBo ThermoFlo Lid Temperature Evaluation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03787212
• Other study ID #: CR-6281
• Status: Terminated
• Phase: N/A
• Start date: December 6, 2018
• Est. completion date: January 28, 2019

Study information

• Verified date: January 2020
• Source: Johnson & Johnson Vision Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective, contralateral, single-site, single-visit unmasked evaluation of external and internal eyelid temperature after treatment with the MiBo ThermoFlo.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: January 28, 2019
• Est. primary completion date: January 28, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Potential subjects must satisfy all the following criteria to be enrolled in the study:

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.

2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.

3. Between 18 and 80 (inclusive) years of age at the time of screening.

4. Subjects must possess a functional/usable pair of spectacles and bring them to the visit (only if applicable - to the investigators discretion).

Exclusion Criteria:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. Currently pregnant or breastfeeding.

2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with participation in the study.

3. Clinically significant (Grade 3 or 4 on the FDA classification scale) slit lamp findings (e.g. corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection).

4. Grade 3-4 Percentage of Partial Meibomian Glands on the Pult 5-point grading scale.

5. Any active Ocular Infection or Inflammation

6. Any history of eyelid surgery or abnormality

7. History of Metal Implants in the Eyelids

8. Any known hypersensitivity or allergic reaction to ultrasound coupling gel.

9. LASIK Surgery within 2 weeks of the Baseline Visit.

10. Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.

11. History of MiBo ThermoFlo or Lipiflow treatment Within the Last 6 months.

12. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).

Related Conditions & MeSH terms

• Dry Eye

Intervention

Device:
• MiBo ThermoFlo
Test Device
• Bruder Mask
Control Device

Locations

Country	Name	City	State
United States	University of Houston, College of Optometry	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Vision Care, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Posterior Eyelid Temperature (Palpebral Conjunctiva)	Ocular surface temperature is usually 34.03±0.51ºC in the normal eye. The temperature required to melt obstructive secretions in the Meibomian glands ranges from 32- 35°C but the more severely obstructed glands present in MGD could require a temperature of >40°C, for effective treatment. there is an approximate 5°C difference in temperature between heat applied on the external eyelid surfaces and that reaches the inner surface of the lids, where the meibomian glands are located. This difference was due to both dissipation of heat while passing through the lid tissues and to constant movement of blood through vasculature wicking heat away from the lids. Therefore, achieving the desired temperature of 40°C at the palpebral conjunctiva requires a constant heat of at least 45°C be maintained on the outer lid surface, a temperature which could be both uncomfortable and risk causing thermal injury to the eyelid skin.	12-minutes post treatment